{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T05:16:57Z","timestamp":1788239817170,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leukotriene receptor antagonists (LTRAs), including montelukast, pranlukast, and zafirlukast, are generally well tolerated and widely used for asthma and allergic rhinitis, but they may cause adverse drug reactions (ADRs). We compared their real-world reporting profiles to identify potential agent-specific safety differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a descriptive and disproportionality analysis of World Health Organization (WHO) VigiAccess data retrieved on August 1, 2025. Reports were included from each drug's first year available in VigiAccess (zafirlukast, 1997; montelukast, 1998; pranlukast, 2002) through August 1, 2025. Report-level demographics were summarized using the number of individual case safety reports (ICSRs), whereas System Organ Class (SOC)- and Preferred Term (PT)-level percentages used the total number of ADR entries for the corresponding drug as the denominator. Reporting odds ratios (RORs), proportional reporting ratios (PRRs), and 95% confidence intervals (CIs) compared each target LTRA with the other two LTRAs combined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified 37,621 ICSRs: montelukast, 33,615 (89.4%); pranlukast, 2,109 (5.6%); and zafirlukast, 1,897 (5.0%). Among 96,624 montelukast ADR entries, the SOC Psychiatric disorders accounted for\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200929,498 (30.5%). Positive PT-level signals included nightmares (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,688, 1.75%; ROR\u2009=\u200945.89, 95% CI: 14.78\u2013142.45; PRR\u2009=\u200945.10, 95% CI: 14.53\u2013139.95), aggression (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,758, 1.82%; ROR\u2009=\u200928.69, 95% CI: 11.92\u201369.03; PRR\u2009=\u200928.18, 95% CI: 11.72\u201367.78), and suicidal ideation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091,901, 1.97%; ROR\u2009=\u200919.41, 95% CI: 9.69\u201338.88; PRR\u2009=\u200919.05, 95% CI: 9.52\u201338.13). Among 2,724 pranlukast ADR entries, Gastrointestinal disorders accounted for\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009809 (29.7%). Zafirlukast showed disproportionate hepatobiliary reporting (ROR\u2009=\u20095.87, 95% CI: 4.88\u20137.06; PRR\u2009=\u20095.72, 95% CI: 4.78\u20136.85). Seven neuropsychiatric PTs were shared across all three agents; their counts, ADR-entry proportions, and RORs ranged from 569 to 2,313, 0.59%\u20132.39%, and 1.22\u201319.41 for montelukast; 2\u201399, 0.07%\u20133.63%, and 0.03\u20131.82 for pranlukast; and 4\u201335, 0.08%\u20130.70%, and 0.06\u20130.32 for zafirlukast.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real-world evidence from spontaneous-report databases suggests differences in the safety-reporting profiles of montelukast, pranlukast, and zafirlukast. However, under-reporting and incomplete clinical information preclude estimation of incidence or causal inference; these findings should be interpreted as safety signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1820058","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:50Z","timestamp":1788236810000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of adverse drug reaction reports for leukotriene receptor antagonists mainly indicated for allergic rhinitis and asthma: a WHO VigiAccess study"],"prefix":"10.3389","volume":"13","author":[{"given":"Youlin","family":"Dong","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, The Second Affiliated Hospital of Jiaxing University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, The Second Affiliated Hospital of Jiaxing University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, The Second Affiliated Hospital of Jiaxing University","place":["Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"874114","DOI":"10.3389\/fmed.2022.874114","article-title":"Allergic rhinitis: a clinical and pathophysiological overview","volume":"9","author":"Nur Husna","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12940-024-01060-8","article-title":"Global patterns of asthma burden related to environmental risk factors during 1990\u20132019: an age-period-cohort analysis for global burden of disease study 2019","volume":"23","author":"Zhang","year":"2024","journal-title":"Environ Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12916-025-03847-z","article-title":"Regular versus as-needed treatments for mild asthma in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"23","author":"Pornsuriyasak","year":"2025","journal-title":"BMC Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/ph3061792","article-title":"Role of leukotrienes and leukotriene modifiers in asthma","volume":"3","author":"Montuschi","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jaci.2009.06.035","article-title":"Genetics and pharmacogenetics of the leukotriene pathway","volume":"124","author":"Tantisira","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2147\/DDDT.S39100","article-title":"Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?","volume":"8","author":"Hon","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3345\/cep.2019.00325","article-title":"Montelukast use over the past 20 years: monitoring of its effects and safety issues","volume":"63","author":"Lee","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-200241020-00003","article-title":"Pharmacokinetic profile of zafirlukast","volume":"41","author":"Dekhuijzen","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1431562","DOI":"10.3389\/fphar.2024.1431562","article-title":"Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases","volume":"15","author":"Liang","year":"2024","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.12932\/AP-030821-1202","article-title":"Adverse drug reactions of montelukast and pranlukast: analysis of the Korea database","volume":"42","author":"Shin","year":"2024","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jaip.2024.09.010","article-title":"Neuropsychiatric events related to montelukast and pranlukast in adults with asthma and rhinitis: a 10-year nationwide population-based study","volume":"13","author":"Jo","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40264-025-01642-6","article-title":"Vigibase: resource profile update with a summary of global patterns and trends in adverse event reports for medicines and vaccines","volume":"49","author":"Brand","year":"2026","journal-title":"Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"key":"B14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00228-017-2396-y","article-title":"Adverse drug reaction reporting: how can drug consumption information add to analyses using spontaneous reports?","volume":"74","author":"Svendsen","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.3390\/ijerph19084447","article-title":"Comparison of patient adverse drug reaction reporting systems in nine selected countries","volume":"19","author":"Worakunphanich","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jaip.2021.02.057","article-title":"A boxed warning for montelukast: the FDA perspective","volume":"9","author":"Clarridge","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-017-0607-1","article-title":"Neuropsychiatric events associated with leukotriene-modifying agents: a systematic review","volume":"41","author":"Law","year":"2018","journal-title":"Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/cns.12596","article-title":"Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders","volume":"22","author":"Ghosh","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1038\/ncomms9466","article-title":"Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug","volume":"6","author":"Marschallinger","year":"2015","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.brainres.2005.06.046","article-title":"Pranlukast, a cysteinyl leukotriene receptor-1 antagonist, protects against chronic ischemic brain injury and inhibits the glial scar formation in mice","volume":"1053","author":"Yu","year":"2005","journal-title":"Brain Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00018-025-05764-z","article-title":"The ADCY1-mediated cAMP signaling pathway mediates functional effects of montelukast treatment in brain organoids","volume":"82","author":"Xu","year":"2025","journal-title":"Cell Mol Life Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1874306401610010036","article-title":"Efficacy and safety of modified pranlukast (Prakanon((R))) compared with pranlukast (Onon((R))): a randomized, open-label, crossover study","volume":"10","author":"Kim","year":"2016","journal-title":"Open Respir Med J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s002280050202","article-title":"Dennis MJ: the single and multiple dose pharmacokinetics of pranlukast in healthy volunteers","volume":"51","author":"Brocks","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejps.2013.11.018","article-title":"Development of a gastric retentive system as a sustained-release formulation of pranlukast hydrate and its subsequent in vivo verification in human studies","volume":"53","author":"Sugihara","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/thx.2007.093955","article-title":"Churg-strauss syndrome and leukotriene antagonist use: a respiratory perspective","volume":"63","author":"Nathani","year":"2008","journal-title":"Thorax"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1789762","DOI":"10.3389\/fphar.2026.1789762","article-title":"Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database","volume":"17","author":"Gianguzzo","year":"2026","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/pds.3622","article-title":"Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database","volume":"23","author":"De Boissieu","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Reddy","year":"2021","journal-title":"Hosp Pharm"},{"key":"B31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf"},{"key":"B32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1820058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:26:51Z","timestamp":1788236811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1820058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":32,"alternative-id":["10.3389\/fmed.2026.1820058"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1820058","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1820058"}}